Please login to the form below

Not currently logged in
Email:
Password:

Simbrinza

This page shows the latest Simbrinza news and features for those working in and with pharma, biotech and healthcare.

Novartis' glaucoma combo cleared in Europe

Novartis' glaucoma combo cleared in Europe

in trials Simbrinza was able to decrease it by 23-37 per cent. ... Simbrinza's EU launch will start in the UK later this quarter, followed by other European markets in the remainder of 2014 and in 2015.

Latest news

  • CHMP backs European approval for six new medicines CHMP backs European approval for six new medicines

    Finally, Novartis' eyecare subsidiary Alcon got a green light for its combination glaucoma therapy Simbrinza (brinzolamide/brimonidine - first approved in the US last year - while Veloxis Pharma got the nod for

  • Novartis lifts 2013 guidance on delay to Diovan generics Novartis lifts 2013 guidance on delay to Diovan generics

    Jimenez also said Novartis had a fertile quarter in terms of its pipeline, with four approvals including Ilaris (canakinumab) for systemic juvenile idiopathic arthritis, Simbrinza (brinzolamide/brimonidine tartrate) for glaucoma, Lucentis

  • FDA approves Alcon eye drug Simbrinza FDA approves Alcon eye drug Simbrinza

    Fixed-combination licensed to treat glaucoma patients in the US. Novartis subsidiary Alcon has been given a boost after US regulators approved its fixed-combination eye treatment Simbrinza Suspension. ... In both studies, Simbrinza achieved a 5mm Hg to

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics